122 results on '"Raber-Durlacher J"'
Search Results
2. Significant salivary changes in relation to oral mucositis following autologous hematopoietic stem cell transplantation
- Author
-
van Leeuwen, S. J. M., Proctor, G. B., Laheij, A. M. G. A., Potting, C. M. J., Smits, O., Bronkhorst, E. M., Hazenberg, M. D., Haverman, T. M., Brennan, M. T., von Bültzingslöwen, I., Raber-Durlacher, J. E., Huysmans, M. C. D. N. J. M., Rozema, F. R., and Blijlevens, N. M. A.
- Published
- 2021
- Full Text
- View/download PDF
3. The salivary proteome in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients: a labelled and label-free proteomics approach
- Author
-
van Leeuwen, S. J. M., primary, Proctor, G. B., additional, Staes, A., additional, Laheij, A. M. G. A., additional, Potting, C. M. J., additional, Brennan, M. T., additional, von Bültzingslöwen, I., additional, Rozema, F. R., additional, Hazenberg, M. D., additional, Blijlevens, N. M. A., additional, Raber-Durlacher, J. E., additional, and Huysmans, M. C. D. N. J. M., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Additional file 3 of The salivary proteome in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients: a labelled and label-free proteomics approach
- Author
-
van Leeuwen, S. J. M., Proctor, G. B., Staes, A., Laheij, A. M. G. A., Potting, C. M. J., Brennan, M. T., von Bültzingslöwen, I., Rozema, F. R., Hazenberg, M. D., Blijlevens, N. M. A., Raber-Durlacher, J. E., and Huysmans, M. C. D. N. J. M.
- Abstract
Additional file 3: Supplementary Tables, 2, 3, 4 and 5 of the DIA experiment. Listing the significant enriched biological processes GO-terms of the significantly regulated proteins in the NON-OM samples across all timepoints; the significantly expressed proteins of the two-way ANOVA of the DIA experiment; the differently expressed proteins during the hospitalization period or outside the hospitalization period); and the top 5 of the significantly enriched biological processes GO-terms of those proteins listed in Supplementary Table 4.
- Published
- 2023
- Full Text
- View/download PDF
5. Additional file 2 of The salivary proteome in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients: a labelled and label-free proteomics approach
- Author
-
van Leeuwen, S. J. M., Proctor, G. B., Staes, A., Laheij, A. M. G. A., Potting, C. M. J., Brennan, M. T., von Bültzingslöwen, I., Rozema, F. R., Hazenberg, M. D., Blijlevens, N. M. A., Raber-Durlacher, J. E., and Huysmans, M. C. D. N. J. M.
- Abstract
Additional file 2: Supplementary Table 1A and 1B. Listing the up- and down-regulated proteins in the ULC-OM pools versus the NON-OM pools and the involved pathways of these up- and down-regulated proteinsof the TMT-labelled experiment.
- Published
- 2023
- Full Text
- View/download PDF
6. Additional file 1 of The salivary proteome in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients: a labelled and label-free proteomics approach
- Author
-
van Leeuwen, S. J. M., Proctor, G. B., Staes, A., Laheij, A. M. G. A., Potting, C. M. J., Brennan, M. T., von Bültzingslöwen, I., Rozema, F. R., Hazenberg, M. D., Blijlevens, N. M. A., Raber-Durlacher, J. E., and Huysmans, M. C. D. N. J. M.
- Abstract
Additional file 1. Experimental details of the TMT-labelled and Label-Free Quantificationexperiment.
- Published
- 2023
- Full Text
- View/download PDF
7. Viral loads and antiviral resistance of herpesviruses and oral ulcerations in hematopoietic stem cell transplant recipients
- Author
-
van der Beek, M T, Laheij, A M G A, Raber-Durlacher, J E, von dem Borne, P A, Wolterbeek, R, van der Blij-de Brouwer, C S, van Loveren, C, Claas, E C J, Kroes, A C M, de Soet, J J, and Vossen, A C T M
- Published
- 2012
- Full Text
- View/download PDF
8. Long-term adverse effects of hematopoietic stem cell transplantation on dental development in children
- Author
-
van der Pas-van Voskuilen, I. G. M., Veerkamp, J. S. J., Raber-Durlacher, J. E., Bresters, D., van Wijk, A. J., Barasch, A., McNeal, S., and Gortzak, R. A. Th.
- Published
- 2009
- Full Text
- View/download PDF
9. PERIODONTAL STATUS and BACTEREMIA in ALLOGENEIC HEMATOPOIETIC STEM CELL RECIPIENTS
- Author
-
Raber-Durlacher, J. E., Laheij, A. M.G.A., Epstein, J. B., Epstein, M., Geerligs, G., Wolffe, G. N., Donnelly, J. P., and Blijlevens, N. M.A.
- Published
- 2013
- Full Text
- View/download PDF
10. Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases
- Author
-
Raber-Durlacher, J. E., Weijl, N. I., Abu Saris, M., de Koning, B., Zwinderman, A. H., and Osanto, S.
- Published
- 2000
- Full Text
- View/download PDF
11. Current practices for management of oral mucositis in cancer patients
- Author
-
Raber-Durlacher, J. E.
- Published
- 1999
- Full Text
- View/download PDF
12. International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV
- Author
-
Singer, S. Amdal, C.D. Hammerlid, E. Tomaszewska, I.M. Castro Silva, J. Mehanna, H. Santos, M. Inhestern, J. Brannan, C. Yarom, N. Fullerton, A. Pinto, M. Arraras, J.I. Kiyota, N. Bonomo, P. Sherman, A.C. Baumann, I. Galalae, R. Fernandez Gonzalez, L. Nicolatou-Galitis, O. Abdel-Hafeez, Z. Raber-Durlacher, J. Schmalz, C. Zotti, P. Boehm, A. Hofmeister, D. Krejovic Trivic, S. Loo, S. Chie, W.-C. Bjordal, K. Brokstad Herlofson, B. Grégoire, V. Licitra, L. on behalf of the EORTC Quality of Life the EORTC Head Neck Cancer Groups
- Subjects
humanities - Abstract
Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life. © 2019 Wiley Periodicals, Inc.
- Published
- 2019
13. International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15
- Author
-
Hjermstad, M.J. Bergenmar, M. Bjordal, K. Fisher, S.E. Hofmeister, D. Montel, S. Nicolatou-Galitis, O. Pinto, M. Raber-Durlacher, J. Singer, S. Tomaszewska, I.M. Tomaszewski, K.A. Verdonck-de Leeuw, I. Yarom, N. Winstanley, J.B. Herlofson, B.B. on behalf of the EORTC QoL Group
- Subjects
humanities - Abstract
Purpose: This international EORTC validation study (phase IV) is aimed at testing the psychometric properties of a quality of life (QoL) module related to oral health problems in cancer patients. Methods: The phase III module comprised 17 items with four hypothesized multi-item scales and three single items. In phase IV, patients with mixed cancers, in different treatment phases from 10 countries completed the EORTC QLQ-C30, the QLQ-OH module, and a debriefing interview. The hypothesized structure was tested using combinations of classical test theory and item response theory, following EORTC guidelines. Test–retest assessments and responsiveness to change analysis (RCA) were performed after 2 weeks. Results: Five hundred seventy-two patients (median age 60.3, 54 % females) were analyzed. Completion took
- Published
- 2016
14. Erratum to: Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases
- Author
-
Raber-Durlacher, J., Weijl, N., Abu Saris, M., de Koning, B., Zwinderman, A., and Osanto, S.
- Published
- 2001
- Full Text
- View/download PDF
15. The pathogenesis of mucositis: updated perspectives and emerging targets.
- Author
-
Bowen, J., Al-Dasooqi, N., Bossi, P., Wardill, H., Van Sebille, Y., Al-Azri, A., Bateman, E., Correa, M. E., Raber-Durlacher, J., Kandwal, A., Mayo, B., Nair, R. G., Stringer, A., ten Bohmer, K., Thorpe, D., Lalla, R. V., Sonis, S., Cheng, K., Elad, S., and Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
- Subjects
MUCOSITIS ,WOUNDS & injuries ,STREETS - Abstract
Mucositis research and treatment are a rapidly evolving field providing constant new avenues of research and potential therapies. The MASCC/ISOO Mucositis Study Group regularly assesses available literature relating to pathogenesis, mechanisms, and novel therapeutic approaches and distils this to summary perspectives and recommendations. Reviewers assessed 164 articles published between January 2011 and June 2016 to identify progress made since the last review and highlight new targets for further investigation. Findings were organized into sections including established and emerging mediators of toxicity, potential insights from technological advances in mucositis research, and perspective. Research momentum is accelerating for mucositis pathogenesis, and with this has come utilization of new models and interventions that target specific mechanisms of injury. Technological advances have the potential to revolutionize the field of mucositis research, although focused effort is needed to move rationally targeted interventions to the clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Oral Complications in Hematopoietic Stem Cell Recipients: The Role of Inflammation
- Author
-
Haverman, T. M., Raber-Durlacher, J. E., Rademacher, W. M. H., Vokurka, S., Epstein, J. B., Huisman, C., Hazenberg, M. D., de Soet, J. J., de Lange, J., and Rozema, F. R.
- Subjects
stomatognathic diseases ,surgical procedures, operative ,Article Subject ,immune system diseases - Abstract
Hematopoietic stem cell transplantation (HSCT) is widely used as a potentially curative treatment for patients with various hematological malignancies, bone marrow failure syndromes, and congenital immune deficiencies. The prevalence of oral complications in both autologous and allogeneic HSCT recipients remains high, despite advances in transplant medicine and in supportive care. Frequently encountered oral complications include mucositis, infections, oral dryness, taste changes, and graft versus host disease in allogeneic HSCT. Oral complications are associated with substantial morbidity and in some cases with increased mortality and may significantly affect quality of life, even many years after HSCT. Inflammatory processes are key in the pathobiology of most oral complications in HSCT recipients. This review article will discuss frequently encountered oral complications associated with HSCT focusing on the inflammatory pathways and inflammatory mediators involved in their pathogenesis.
- Published
- 2014
- Full Text
- View/download PDF
17. Alternative Chitosan Based Drug Delivery System to Fight Oral Mucositis: Synergy of Conventional and Bioactives Towards the Optimal Solution
- Author
-
Epstein, J.B., Barasch, A., Brennan, M., Raber-Durlacher, J., Bulzingslowen, I. von, Bensadoun, R.J., and Nair, R.G.
- Published
- 2012
18. The EORTC QLQ-OH17: A supplementary module to the EORTC QLQ-C30 for assessment of oral health and quality of life in cancer patients
- Author
-
Hjermstad, M.J. Bergenmar, M. Fisher, S.E. Montel, S. Nicolatou-Galitis, O. Raber-Durlacher, J. Singer, S. Verdonck-De Leeuw, I. Weis, J. Yarom, N. Herlofson, B.B.
- Subjects
humanities - Abstract
Aims: Assessment of oral and dental problems is seldom routine in clinical oncology, despite the potential negative impact of these problems on nutritional status, social function and quality of life (QoL). The aim was to develop a supplementary module to the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30) focusing on oral health and related QoL issues in all cancer diagnoses. Methods: The module development followed the EORTC guidelines. Phases 1&2 were conducted in France, Germany, Greece, Netherlands, Norway and United Kingdom, while seven countries representing seven languages were included in Phase 3. Results: Eighty-five QoL-items were identified from systematic literature searches. Semi-structured interviews with health-care professionals experienced in oncology and oral/dental care (n = 18) and patients (n = 133) resulted in a provisional module with 41 items. In phase 3 this was further tested in 178 European patients representing different phases of disease and treatment. Results from the interviews, clinical experiences and statistical analyses resulted in the EORTC QLQ-OH17. The module consists of 17 items conceptualised into four multi-item scales (pain/discomfort, xerostomia, eating, information) and three single items related to use of dentures and future worries. Conclusion: This study provides a useful tool intended for use in conjunction with the EORTC QLQ-C30 for assessment of oral and dental problems. The increased awareness may lead to proper interventions, thereby preventing more serious problems and negative impact on QoL. The reliability and validity, the cross-cultural applicability and the psychometric properties of the module will be tested in a larger international study. © 2012 Elsevier Ltd. All rights reserved.
- Published
- 2012
19. The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial
- Author
-
Elad, S., Epstein, J.B., Raber-Durlacher, J., Donnelly, P., Strahilevitz, J., Oral and Maxillofacial Surgery, Parodontologie (OII, ACTA), and Periodontology
- Subjects
Invasive mycoses and compromised host Translational research [N4i 2] ,SDG 3 - Good Health and Well-being - Abstract
BACKGROUND:Cytotoxic chemotherapy induces changes in the oral microflora that may cause oral and systemic infections in myelosuppressed cancer patients. These complications prompted us to assess the antimicrobial activity of a topical Iseganan HCl mouthwash vs. placebo on the aerobic and facultatively anaerobic oral flora in these patients.METHODS:Two hundred and twenty-five chemotherapy patients were recruited into a randomized, double-blind, placebo-controlled trial, conducted at multiple centers. The study compared the antimicrobial efficacy of Iseganan HCl vs. placebo (95% of the Iseganan and 97% of the control group received myeloablative chemotherapy). Iseganan HCl 9 mg/3 ml was administered as a swish and swallow solution, six times daily for 21-28 days. Microbial cultures were made before and after the daily Iseganan mouth rinse on the first and final days of chemotherapy.RESULTS:The reduction in total microbial load after the first day of treatment was statistically significant (1.59 vs. 0.18 log10 CFU for the Iseganan HCl and placebo groups, respectively, P < 0.0001). Iseganan HCl rinse had a cumulative effect demonstrated by the significant difference between the two groups on the last day of the study (i.e. completion of Iseganan daily treatment) (P < 0.05). The reduction was mainly due to decreased densities of viridans streptococci, non-hemolytic streptococci, and yeasts. The minimal inhibitory concentration (MIC) of Iseganan HCl remained the same throughout the course of treatment.CONCLUSIONS:Topical Iseganan HCl significantly reduces the total oral aerobic bacterial, streptococcal, and yeast load. Its potential as an oral antimicrobial agent in preventing these types of infections is clear.
- Published
- 2012
- Full Text
- View/download PDF
20. OC-045: Best practices for supportive care during chemo-radiotherapy in head and neck cancer patients
- Author
-
Bossi, P., primary, Russi, E., additional, Numico, G., additional, Vermorken, J.B., additional, Murphy, B., additional, Raber-Durlacher, J., additional, Langendijk, J.A., additional, Rognoni, C., additional, Quaglini, S., additional, and Licitra, L., additional
- Published
- 2015
- Full Text
- View/download PDF
21. Oral complications of haematopoietic stem cell transplantation
- Author
-
Elad, S., Raber-Durlacher, J., Shapira, M.Y., Davies, A.N., Epstein, J.B., and Parodontologie (OUD, ACTA)
- Published
- 2010
22. Hematopoëtische stamceltransplantaties en orale problemen
- Author
-
Raber-Durlacher, J. E., von dem Borne, P. A., Stokman, M. A., Gortzak, R. A. Th, and Other departments
- Abstract
New haematopoietic stem cell transplantation procedures make the treatment available to patients who previously did not qualify, such as the elderly. In addition, the spectrum of oral complications associated with haematopoietic stem cell transplantation has altered as a result of the recent developments. This article is a review of the main principles of haematopoietic stem cell transplantation and provides information on oral complications which may develop, such as mucositis, infections, bleeding, graft-versus-host disease, xerostomia, hyposalivation, altered taste, secondary tumors, osteoporosis, osteonecrosis and growing and developing disturbancies. Finally, the role of dental care providers in cases of haematopoietic stem cell transplantation is addressed
- Published
- 2009
23. Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases (vol 8, pg 266, 2000)
- Author
-
Raber-Durlacher, J. E., Weijl, N. J., Saris, M. A., de Koning, B., Zwinderman, A. H., Osanto, S., and Other departments
- Published
- 2001
24. Znachenie éndokrinnykh faktorov i mikroorganizmov v razvitii gingivita beremennykh
- Author
-
Abraham-Inpijn, L., Polsacheva, O. V., Raber-Durlacher, J. E., and Other departments
- Subjects
stomatognathic diseases ,stomatognathic system - Abstract
40-100% of pregnant women suffer from the co-called pregnancy gingivitis. The cause of pregnancy gingivitis is possible multicausal: increased plasma female sex-hormones, alteration in dental plague and perhaps Prevotella intermedia in the subgingival plague, together with alteration of immunoresponse. Increasing levels of progesterone in the gingiva as well as estrogens due to specific receptors affect vascular permeability and exudation, provoke stasis of microcirculation, increase prostaglandine E2 formation in human gingiva. Decreased gingival keratinization and capability of cell regeneration may affect the epithelial barrier. This can perhaps explain the direct dependence between progesterone and estrogens increasing and the intensification of gingivitis clinical manifestation. The experimental gingivitis model of women during pregnancy and post-partum showed identical amounts of dental plague, but clinical manifestations were more intense during pregnancy and they had a relation with increasing P. Intermedia, no statistical significance was shown in the proportion of P. gingivalis. Increasing steroid hormones can substitute for the naphtoquinone requirement of P. intermedia. Optimal oral hygiene performed during pregnancy reduced gingival swelling, redness and bleeding tendency to levels which can be considered as physiologic for the pregnant state
- Published
- 1996
25. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients.
- Author
-
Sonis, S.T., Elting, L.S., Keefe, D., Peterson, D.E., Schubert, M., Hauer-Jensen, M., Bekele, B.N., Raber-Durlacher, J., Donnelly, J.P., Rubenstein, E.B., Sonis, S.T., Elting, L.S., Keefe, D., Peterson, D.E., Schubert, M., Hauer-Jensen, M., Bekele, B.N., Raber-Durlacher, J., Donnelly, J.P., and Rubenstein, E.B.
- Abstract
Contains fulltext : 57940.pdf (publisher's version ) (Closed access), BACKGROUND: A frequent complication of anticancer treatment, oral and gastrointestinal (GI) mucositis, threatens the effectiveness of therapy because it leads to dose reductions, increases healthcare costs, and impairs patients' quality of life. The Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology assembled an international multidisciplinary panel of experts to create clinical practice guidelines for the prevention, evaluation, and treatment of mucositis. METHODS: The panelists examined medical literature published from January 1966 through May 2002, presented their findings at two separate conferences, and then created a writing committee that produced two articles: the current study and another that codifies the clinical implications of the panel's findings in practice guidelines. RESULTS: New evidence supports the view that oral mucositis is a complex process involving all the tissues and cellular elements of the mucosa. Other findings suggest that some aspects of mucositis risk may be determined genetically. GI proapoptotic and antiapoptotic gene levels change along the GI tract, perhaps explaining differences in the frequency with which mucositis occurs at different sites. Studies of mucositis incidence in clinical trials by quality and using meta-analysis techniques produced estimates of incidence that are presented herein for what to our knowledge may be a broader range of cancers than ever presented before. CONCLUSIONS: Understanding the pathobiology of mucositis, its incidence, and scoring are essential for progress in research and care directed at this common side-effect of anticancer therapies.
- Published
- 2004
26. Xerostomia and chronic oral complications among patients treated with haematopoietic stem cell transplantation
- Author
-
Brand, H. S., primary, Bots, C. P., additional, and Raber-Durlacher, J. E., additional
- Published
- 2009
- Full Text
- View/download PDF
27. Experimental gingivitis during pregnancy and post-partum: clinical, endocrinological, and microbiological aspects
- Author
-
Raber-Durlacher, J. E., primary, Steenbergen, T. J. M., additional, Velden, U., additional, Graaff, J., additional, and Abraham-Inpijn, L., additional
- Published
- 1994
- Full Text
- View/download PDF
28. Efficient and unbiased estimation of volume and area of tissue components and cell number in gingival biopsies
- Author
-
Verwer, R. W. H., primary and Raber-Durlacher, J. E., additional
- Published
- 1993
- Full Text
- View/download PDF
29. Patient-reported outcomes for immediate identification of dental care needs
- Author
-
Güneri Pelin, Epstein Joel B., Raber-Durlacher Judith E., Çankaya Hülya, Boyacıoğlu Hayal, and Barasch Andrei
- Subjects
dental care ,health care delivery ,oral health ,patient outcomes assessment ,special care ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Aim: Dental treatment is necessary in oncology patients since pre-existing oro-dental disease may influence cancer treatment and prognosis. This study investigated the applicability of two indices in reflecting the actual oral health status of 100 non-cancer patients who were admitted for dental complaints/routine controls.
- Published
- 2015
- Full Text
- View/download PDF
30. Renale osteodystrofie. I. Calcium- en fosfaatstofwisseling; normale toestand
- Author
-
Raber-Durlacher, J. E., Schächter, M. E., Abraham-Inpijn, L., Bras, J., van Ooij, C. P., and Other departments
- Published
- 1983
31. Renale osteodystrofie. II. Pathologie en röntgendiagnostiek
- Author
-
Raber-Durlacher, J. E., Schächter, M. E., Abraham-Inpijn, L., Bras, J., van Ooij, C. P., Wilmink, J. M., and Other departments
- Published
- 1983
32. Cytostatica bij kinderen. Preventie van orale complicaties
- Author
-
Raber-Durlacher, J. E., Abraham-Inpijn, L., Lustig, K. H., Behrendt, H., and Other departments
- Subjects
stomatognathic diseases - Abstract
Especially in children the frequency of oral complications associated with cancer chemotherapy is high. The dentist plays an important role in preventing or reducing these sometimes life-threatening problems. Oral symptoms of the underlying disease, oral sequelae from chemotherapy, patient-related factors and a preventive oral care program will be discussed
- Published
- 1989
33. Summary of: Xerostomia and chronic oral complications among patients treated with haematopoietic stem cell transplantation.
- Author
-
Brand, H. S., Bots, C. P., and Raber-Durlacher, J. E.
- Subjects
HEMATOPOIETIC stem cell transplantation ,COMPLICATIONS from organ transplantation ,CROSS-sectional method ,STOMATITIS ,DENTAL research ,ORAL hemorrhage ,ORAL diseases ,ORAL mucosa - Abstract
Objective To assess the severity of xerostomia (subjective dry mouth) in haematopoietic stem cell transplantation (HSCT) patients and to investigate the association of xerostomia with other chronic oral complications.Design Cross-sectional study.Study participants and methods Participants were 48 patients with a history of HSCT recruited among members of the Dutch Stem Cell Transplantation Contact Group, and a comparison group of 41 age- and sex-matched individuals. Data were collected using the Xerostomia Inventory (XI score) and a seven-item oral health questionnaire.Results HSCT patients had a higher XI score than the comparison group, and a greater severity of several oral complaints: painful oral mucosa, altered taste, limited opening of the mouth and problems with tooth brushing. HSCT patients did not report greater pain during cold stimulation of teeth, chipped and cracked teeth or bleeding gums. In HSCT patients, the XI score correlated significantly with the severity of oral mucosal pain, altered taste, limited opening of the mouth, painful teeth following cold stimuli, chipped or cracked teeth, problems with tooth brushing and bleeding gums. In the comparison group, no correlations were observed between XI score and these oral problems.Conclusion HSCT patients have more severe xerostomia, which is associated with other oral complaints. Dental professionals should monitor these patients post-transplant for oral complications. Symptoms of dry mouth should be relieved and secondary complications should be prevented. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
34. Sepsis in head and neck cancer patients treated with chemotherapy and radiation: literature review and consensus
- Author
-
Almalina Bacigalupo, F. Crippa, Marco Merlano, Elvio G. Russi, Stefania Musso, Jacques Bernier, Vitaliana De Sanctis, Orietta Caspiani, Anna Merlotti, Maria Grazia Ghi, Francesco Moretto, Gianmauro Numico, Antonio Cascio, Judith E. Raber-Durlacher, Lisa Licitra, Paolo Bossi, Jan B. Vermorken, Nerina Denaro, Barbara A. Murphy, Marco Ranieri, Stefano Pergolizzi, R. Phillip Dellinger, Aurora Mirabile, Michela Buglione, Maxillofacial Surgery (AMC), Oral Medicine, Mirabile, A., Numico, G., Russi, E., Bossi, P., Crippa, F., Bacigalupo, A., De Sanctis, V., Musso, S., Merlotti, A., Ghi, M., Merlano, M., Licitra, L., Moretto, F., Denaro, N., Caspiani, O., Buglione, M., Pergolizzi, S., Cascio, A., Bernier, J., Raber-durlacher, J., Vermorken, J., Murphy, B., Ranieri, M., Dellinger, R., Russi, E.G., Ghi, M.G., Merlano, M.C., Raber-Durlacher, J., Vermorken, J.B., Ranieri, M.V., Dellinger, R.P., MKA AMC (OII, ACTA), Orale Geneeskunde (OII, ACTA), and Faculteit der Geneeskunde
- Subjects
cancer patient ,pathogenesi ,positron emission tomography ,healthcare associated infection ,Settore MED/06 - Oncologia Medica ,patient monitoring ,radiodiagnosi ,medicine.medical_treatment ,Chemotherapy ,Head and neck cancer ,Radiotherapy ,Sepsis ,thrombocytopenia ,Review ,blood culture ,organ injury ,medical terminology ,Medicine ,metabolic acidosi ,C reactive protein ,Head and Neck Neoplasm ,medical specialist ,treatment withdrawal ,consensus development ,Hematology ,clinical practice ,systemic inflammatory response syndrome ,Italy ,Oncology ,Head and Neck Neoplasms ,laboratory test ,thrombocytosi ,chemically induced ,chemotherapy ,head and neck cancer ,radiotherapy ,sepsis ,oncology ,hematology ,geriatrics and gerontology ,organ perfusion ,hospitalization ,Human ,sepsis, Head and Neck Neoplasm ,medicine.medical_specialty ,Settore MED/17 - Malattie Infettive ,Sepsi ,bacterium culture ,diagnostic approach route ,fluorodeoxyglucose ,cancer chemotherapy ,SDG 3 - Good Health and Well-being ,cancer radiotherapy ,follow up ,Humans ,infection risk ,Intensive care medicine ,procalcitonin, antimicrobial therapy ,business.industry ,disease predisposition ,lactic acid ,Geriatrics and Gerontology ,medicine.disease ,mortality ,Delphi study ,Radiation therapy ,inflammation ,incidence ,hyperglycemia ,Human medicine ,business - Abstract
The reporting of infection/sepsis in chemo/radiation-treated head and neck cancer patients is sparse and the problem is underestimated. A multidisciplinary group of head and neck cancer specialists from Italy met with the aim of reaching a consensus on a clinical definition and management of infections and sepsis. The Delphi appropriateness method was used for this consensus. External expert reviewers then evaluated the conclusions carefully according to their area of expertise. The paper contains seven clusters of statements about the clinical definition and management of infections and sepsis in head and neck cancer patients, which had a consensus. Furthermore, it offers a review of recent literature in these topics. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
- Published
- 2015
- Full Text
- View/download PDF
35. The pathogenesis of mucositis
- Author
-
Noor Al-Dasooqi, Judith E. Raber-Durlacher, Maria Elvira Pizzigatti Correa, K. ten Bohmer, Andrea M. Stringer, Karis Kin Fong Cheng, Hannah R. Wardill, Abhishek Kandwal, Joanne M. Bowen, Rajesh V. Lalla, Paolo Bossi, Bronwen J. Mayo, Abdul Rahman Al-Azri, Raj G. Nair, Daniel Thorpe, Isoo, Y Z A Van Sebille, Emma Bateman, Stephen T. Sonis, Sharon Elad, Oral Medicine, Maxillofacial Surgery (AMC), Bowen, J, Al-Dasooqi, N, Bossi, P, Wardill, H, Van Sebille, Y, Al-Azri, A, Bateman, E, Correa, ME, Raber-Durlacher, J, Kandwal, A, Mayo, B, Nair, RG, Stringer, A, ten Bohmer, K, Thorpe, D, Lalla, RV, Sonis, S, Cheng, K, Elad, S, Orale Geneeskunde (OII, ACTA), and MKA AMC (OII, ACTA)
- Subjects
Mucositis ,Technology ,medicine.medical_specialty ,Psychological intervention ,microbiome ,Pathogenesis ,Permeability ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,perspectives ,Neoplasms ,medicine ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Stomatitis ,business.industry ,Nursing research ,pathogenesis ,Targeted interventions ,medicine.disease ,Microbiome ,Perspectives ,mucositis ,Oncology ,030220 oncology & carcinogenesis ,technology ,permeability ,business - Abstract
Mucositis research and treatment are a rapidly evolving field providing constant new avenues of research and potential therapies. The MASCC/ISOO Mucositis Study Group regularly assesses available literature relating to pathogenesis, mechanisms, and novel therapeutic approaches and distils this to summary perspectives and recommendations. Reviewers assessed 164 articles published between January 2011 and June 2016 to identify progress made since the last review and highlight new targets for further investigation. Findings were organized into sections including established and emerging mediators of toxicity, potential insights from technological advances in mucositis research, and perspective. Research momentum is accelerating for mucositis pathogenesis, and with this has come utilization of new models and interventions that target specific mechanisms of injury. Technological advances have the potential to revolutionize the field of mucositis research, although focused effort is needed to move rationally targeted interventions to the clinical setting. Refereed/Peer-reviewed
- Published
- 2019
- Full Text
- View/download PDF
36. Updated clinical practice guidelines for the prevention and treatment of mucositis
- Author
-
Dorothy M. K. Keefe, Linda S. Elting, Deborah B. McGuire, Mark M. Schubert, Cesar A. Migliorati, Douglas E. Peterson, Joel B. Epstein, Judith E. Raber-Durlacher, Ronald D. Hutchins, Stephen T. Sonis, Keefe, Dorothy, Schubert, Mark, Elting, L, Sonis, Stephen, Epstein, Joel, Raber-Durlacher, J, Migliorati, Cesar, McGuire, Deborah, Hutchins, Ronald, and Peterson, Douglas
- Subjects
Mucositis ,Cancer Research ,medicine.medical_specialty ,Radiation proctitis ,Population ,MEDLINE ,Antineoplastic Agents ,Risk Factors ,Neoplasms ,medicine ,Humans ,Intensive care medicine ,education ,education.field_of_study ,Radiotherapy ,business.industry ,Cancer ,Amifostine ,medicine.disease ,Surgery ,Transplantation ,Oncology ,Palifermin ,business ,medicine.drug - Abstract
Considerable progress in research and clinical application has been made since the original guidelines for managing mucositis in cancer patients were published in 2004, and the first active drug for the prevention and treatment of this condition has been approved by the United States Food and Drug Administration and other regulatory agencies in Europe and Australia. These changes necessitate an updated review of the literature and guidelines. Panel members reviewed the biomedical literature on mucositis published in English between January 2002 and May 2005 and reached a consensus based on the criteria of the American Society of Clinical Oncology. Changes in the guidelines included recommendations for the use of palifermin for oral mucositis associated with stem cell transplantation, amifostine for radiation proctitis, and cryotherapy for mucositis associated with high-dose melphalan. Recommendations against specific practices were introduced: Systemic glutamine was not recommended for the prevention of gastrointestinal mucositis, and sucralfate and antimicrobial lozenges were not recommended for radiation-induced oral mucositis. Furthermore, new guidelines suggested that granulocyte-macrophage-colony stimulating factor mouthwashes not be used for oral mucositis prevention in the transplantation population. Advances in mucositis treatment and research have been complemented by an increased rate of publication on mucosal injury in cancer. However, additional and sustained efforts will be required to gain a fuller understanding of the pathobiology, impact on overall patient status, optimal therapeutic strategies, and improved educational programs for health professionals, patients, and caregivers. These efforts are likely to have significant clinical and economic impact on the treatment of cancer patients. Cancer 2007;109:820-31. (c) 2007 American Cancer Society.
- Published
- 2007
37. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis
- Author
-
Richard M. Logan, Judith E. Raber-Durlacher, Michael T. Brennan, Dorothy M. K. Keefe, Andrea M. Stringer, Inger von Bültzingslöwen, Fred K. L. Spijkervet, Parodontologie (OUD, ACTA), Bultzingslowen, Inger Von, Brennan, Michael, Spijkervet, Fred, Logan, Richard, Stringer, Andrea Marie, Keefe, Dorothy, and Raber-Durlacher, J
- Subjects
Oncology ,Gastrointestinal Diseases ,medicine.medical_treatment ,Mouthwashes ,chemotherapy ,Medical Oncology ,law.invention ,DOUBLE-BLIND ,Mice ,Randomized controlled trial ,law ,Neoplasms ,cytokine ,Medicine ,Growth Substances ,Clinical Trials as Topic ,Evidence-Based Medicine ,growth factor ,Pharmacology and Pharmaceutical Sciences ,COLONY-STIMULATING FACTOR ,Primary Prevention ,alimentary) ,Cytokine ,Systematic review ,mucositis (oral ,Practice Guidelines as Topic ,cancer therapy ,Cytokines ,CLINICAL-PRACTICE GUIDELINES ,RECEIVING RADIATION-THERAPY ,Whole-Body Irradiation ,Mucositis ,medicine.medical_specialty ,Fibroblast Growth Factor 7 ,mucosal barrier injury ,INTESTINAL DAMAGE ,Antineoplastic Agents ,NECK-CANCER PATIENTS ,Internal medicine ,FACTOR GM-CSF ,Animals ,Humans ,CHEMOTHERAPY-INDUCED MUCOSITIS ,Stomatitis ,Chemotherapy ,Radiotherapy ,business.industry ,Granulocyte-Macrophage Colony-Stimulating Factor ,Cancer ,mucositis management ,STEM-CELL TRANSPLANTATION ,Evidence-based medicine ,medicine.disease ,gastrointestinal ,RANDOMIZED-TRIAL ,Radiation therapy ,Disease Models, Animal ,Immunology ,Drug Evaluation ,mouth ,business ,Stem Cell Transplantation - Abstract
Goals of work: Growth factors and cytokines may be useful in preventing chemotherapy (CT)- and radiotherapy (RT)-induced oral and gastrointestinal mucositis. Two systematic reviews of the medical literature on growth factors and cytokines for the amelioration of CT- and RT-induced mucositis throughout the alimentary tract were performed by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology. The aim of these evidence-based scientific reviews was to critically evaluate the literature and create evidence-based guidelines for the use of growth factors and cytokines in the prevention or treatment of CT- and RT-induced mucositis. Method: The two reviews covered articles on clinical trials from January 1966 through May 2002 and preclinical studies from June 2002 through May 2005, respectively. The systematic review process was based on a well-established method for evaluating scientific literature. Main results: The number of articles in the first review was 29. In the second review, 23 articles were evaluated, 14 preclinical and 9 clinical studies. It was concluded from the first review that there was no sufficient evidence to provide any recommendations for clinical practice guidelines regarding growth factors and cytokines. From the second review, a guideline could be presented recommending the use of recombinant human keratinocyte growth factor-1 (palifermin) to prevent oral mucositis in patients receiving high-dose CT and total body irradiation followed by stem cell transplantation for haematological malignancies. A guideline could also be provided suggesting that granulocyte macrophage colony-stimulating factor mouthwash not be used for the prevention of oral mucositis in the transplant setting with high-dose CT and autologous or allogeneic stem cell transplantation. Conclusions: These systematic reviews have provided clarity and shown exciting new results. Further studies will provide new options for this debilitating side-effect of cancer therapy.
- Published
- 2006
- Full Text
- View/download PDF
38. The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change.
- Author
-
Singer S, Hammerlid E, Tomaszewska IM, Amdal CD, Herlofson BB, Santos M, Castro Silva J, Mehanna H, Fullerton A, Young T, Fernandez Gonzalez L, Inhestern J, Pinto M, Arraras JI, Yarom N, Bonomo P, Baumann I, Galalae R, Nicolatou-Galitis O, Kiyota N, Raber-Durlacher J, Salem D, Fabian A, Boehm A, Krejovic-Trivic S, Chie WC, Taylor KJ, Sherman AC, Licitra L, Machiels JP, and Bjordal K
- Subjects
- Humans, Male, Female, Middle Aged, Surveys and Questionnaires, Aged, Europe, Adult, Minimal Clinically Important Difference, Head and Neck Neoplasms therapy, Head and Neck Neoplasms psychology, Quality of Life
- Abstract
Introduction: Minimal important change estimates (MIC) are useful for interpreting results of clinical research with quality of life (QoL) as an endpoint. For the European Organisation for Research and Treatment of Cancer head and neck cancer module, the EORTC QLQ-HN43, no such thresholds are established., Methods: Head and neck cancer patients under active treatment (n = 503) from 15 countries completed the EORTC QLQ-HN43 three times (t1: before treatment, t2: three months after t1, t3: six months after t1). A subgroup completed a Subjective Significance Questionnaire (SSQ), indicating experienced change from the previous time point in four QoL domains. QoL was assumed to deteriorate after t1 and improve again until t3. The MIC was established using the average of mean differences in SSQ groups (MIC
mean ) and estimates based on logistic regressions (MICpredict ). Additionally, minimal detectable changes (MDC) were computed using 0.5 standard deviation and standard error of the mean., Results: For swallowing, speech, dry mouth, and global QoL, the MIC for deterioration were 13, 14, 26, and 10 respectively. The MIC for improvement were 8 (swallowing), 6 (dry mouth), and 5 (global QoL); no MIC for speech improvement can be presented because of insufficient correlation between change score and anchor. The MDC estimates for deterioration were 15, 14, 15, and 11. For improvement, the MDC estimates were 13, 14, 14, and 11., Conclusions: Our results underline that no single MIC or MDC can be applied to all EORTC QLQ-HN43 scales, and that the MIC for deterioration seems larger than those for improvement., Competing Interests: Declaration of Competing Interest Authors declare they have no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
39. Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study.
- Author
-
Abdalla-Aslan R, Bonomo P, Keefe D, Blijlevens N, Cao K, Cheung YT, Fregnani ER, Miller R, Raber-Durlacher J, Epstein J, Van Sebille Y, Kauark-Fontes E, Kandwal A, McCurdy-Franks E, Finkelstein J, McCarvell V, Zadik Y, Ottaviani G, Amaral Mendes R, Speksnijder CM, Wardill HR, and Bossi P
- Abstract
Background: Mucositis is a common and highly impactful side effect of conventional and emerging cancer therapy and thus the subject of intense investigation. Although common practice, mucositis assessment is heterogeneously adopted and poorly guided, impacting evidence synthesis and translation. The Multinational Association of Supportive Care in Cancer (MASCC) Mucositis Study Group (MSG) therefore aimed to establish expert recommendations for how existing mucositis assessment tools should be used, in clinical care and trials contexts, to improve the consistency of mucositis assessment., Methods: This study was conducted over two stages (January 2022-July 2023). The first phase involved a survey to MASCC-MSG members (January 2022-May 2022), capturing current practices, challenges and preferences. These then informed the second phase, in which a set of initial recommendations were prepared and refined using the Delphi method (February 2023-May 2023). Consensus was defined as agreement on a parameter by >80% of respondents., Findings: Seventy-two MASCC-MSG members completed the first phase of the study (37 females, 34 males, mainly oral care specialists). High variability was noted in the use of mucositis assessment tools, with a high reliance on clinician assessment compared to patient reported outcome measures (PROMs, 47% vs 3%, 37% used a combination). The World Health Organization (WHO) and Common Terminology Criteria for Adverse Events (CTCAE) scales were most commonly used to assess mucositis across multiple settings. Initial recommendations were reviewed by experienced MSG members and following two rounds of Delphi survey consensus was achieved in 91 of 100 recommendations. For example, in patients receiving chemotherapy, the recommended tool for clinician assessment in clinical practice is WHO for oral mucositis (89.5% consensus), and WHO or CTCAE for gastrointestinal mucositis (85.7% consensus). The recommended PROM in clinical trials is OMD/WQ for oral mucositis (93.3% consensus), and PRO-CTCAE for gastrointestinal mucositis (83.3% consensus)., Interpretation: These new recommendations provide much needed guidance on mucositis assessment and may be applied in both clinical practice and research to streamline comparison and synthesis of global data sets, thus accelerating translation of new knowledge into clinical practice., Funding: No funding was received., Competing Interests: The authors report no potential conflicts of interests to declare., (© 2024 Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
40. [A PhD completed. Long-term effects of childhood cancer therapy on oral health].
- Author
-
Stolze J, Brand HS, Raber-Durlacher JE, and Bresters D
- Subjects
- Humans, Child, Oral Health, Survivors, Delivery of Health Care, Risk Factors, Neoplasms radiotherapy
- Abstract
In recent years, the five-year survival rate for childhood cancer has increased to about 80%. However, childhood cancer therapy can have serious long-term adverse effects on general health later in life. Of survivors, 75% experience 1 or more late effects. This PhD research aimed to gain more insight into the long-term effects on oral health of childhood cancer therapy, 15 years or more after diagnosis. This study, which is part of the Dutch Childhood Cancer Survivor Study Late Effects 2 (DCCSS LATER 2 Study), showed that oral complications such as dental developmental disorders and hyposalivation occur frequently. Most important risk factors were head and neck radiotherapy of the salivary glands, (alkylating) cytostatic agents, and age at the time of the cancer diagnosis. Dentists should be aware of childhood cancer in the medical history of their patient and of the type of therapy received. Regular dental visits are an essential part of long-term follow-up care of childhood cancer survivors.
- Published
- 2024
- Full Text
- View/download PDF
41. Hemodynamics of the oral mucosa during cooling: A crossover clinical trial.
- Author
-
Walladbegi J, Raber-Durlacher JE, Jontell M, and Milstein DMJ
- Abstract
Objective: Oral cryotherapy is used to prevent the onset of oral mucositis, a common and debilitating adverse effect following cancer chemotherapy. A protective mechanism associated with oral cooling is thought to be mediated through reduced tissue microcirculation. The aim of the present study was to examine the underlying mechanism associated with oral mucosal cooling by measuring oral microcirculation and tissue oxygen saturation after cooling with ice chips (IC) and an intraoral cooling device (ICD)., Study Design: In a single-center randomized crossover study, 10 healthy volunteers were assigned (1:1) randomly to the order in which the two intraoral cooling procedures (IC/ICD) were to be commenced. On day 1, half of the study participants started with IC and then crossed over to intraoral cooling with the ICD on day 2, while the other half of the participants undertook the same two procedures in the reverse order. Total and functional capillary density (T/FCD) and tissue oxygen saturation (StO
2 ) measurements were obtained at baseline and 30 min following oral cooling., Results: Following 30 min of oral cooling, a statistically significant difference was found for FCD between IC and ICD (percentage points; +2 vs. -13; p < 0.05). A statistically significant decrease in StO2 was observed with both IC and ICD (%; 13 vs. 10) after 30 min of cooling as compared to baseline ( p < 0.05). As for the participants' preference the ICD was preferred over IC by 9 out of 10 participants ( p = 0.021)., Conclusions: Both microcirculation parameters and tissue oxygen saturation are altered in conjunction with oral cooling, indicating their potential mechanistic contribution towards cryoprevention of oral mucositis., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. J. Walladbegi reports personal fees from BrainCool AB. Dr. M. Jontell reports consultation fee from Braincool AB and grants from Braincool AB. Drs. J.E. Raber-Durlacher and D.M.J. Milstein have no conflicts of interest to disclose., (© 2023 The Authors.)- Published
- 2023
- Full Text
- View/download PDF
42. Tooth Formation as Experimental Model to Study Chemotherapy on Tissue Development: Effect of a Specific Dose of Temozolomide/Veliparib.
- Author
-
Al-Ansari S, Jalali R, Bronckers ALJJ, van Tellingen O, Raber-Durlacher J, Nadjmi N, Brook AH, de Lange J, and Rozema FR
- Subjects
- Animals, Benzimidazoles, Claudin-1 genetics, Mice, Temozolomide pharmacology, Models, Theoretical, Odontogenesis
- Abstract
Background: Chemotherapy treatment of cancer in children can influence formation of normal tissues, leading to irreversible changes in their structure and function. Tooth formation is susceptible to several types of chemotherapy that induce irreversible changes in the structure of enamel, dentin and dental root morphology. These changes can make the teeth more prone to fracture or to caries when they have erupted. Recent studies report successful treatment of brain tumors with the alkylating drug temozolomide (TMZ) in combination with veliparib (VLP) in a glioblastoma in vivo mouse model. Whether these drugs also affect tooth formation is unknown., Aim: In this study the effect of TMZ/VLP on incisor formation was investigated in tissue sections of jaws from mice and compared with mice not treated with these drugs., Materials and Method: The following aspects were studied using immunohistochemistry of specific protein markers including: (1) proliferation (by protein expression of proliferation marker Ki67) (2) a protein involved in paracellular ion transport (expression of tight junction (TJ) protein claudin-1) and (3) in transcellular passage of ions across the dental epithelium (expression of Na+, K+ 2Cl- cotransporter/NKCC1)., Results: Chemotherapy with TMZ/VLP strongly reduced immunostaining for claudin-1 in distal parts of maturation ameloblasts. No gross changes were found in the treated mice, either in cell proliferation in the dental epithelium at the cervical loop or in the immunostaining pattern for NKCC1 in (non-ameloblastic) dental epithelium. The salivary glands in the treated mice contained strongly reduced immunostaining for NKCC1 in the basolateral membranes of acinar cells., Discussion/conclusions: Based on the reduction of claudin-1 immunostaining in ameloblasts, TMZ/VLP may potentially influence forming enamel by changes in the structure of TJs structures in maturation ameloblasts, structures that are crucial for the selective passage of ions through the intercellular space between neighboring ameloblasts. The strongly reduced basolateral NKCC1 staining seen in fully-grown salivary glands of TMZ/VLP-treated mice suggests that TMZ/VLF could also influence ion transport in adult saliva by the salivary gland epithelium. This may cause treated children to be more susceptible to caries.
- Published
- 2022
- Full Text
- View/download PDF
43. [Oral chronic graft versus host disease, what is it and how is it treated?]
- Author
-
Laheij AMGA, Raber-Durlacher JE, Hazenberg MD, Schoordijk MCE, Huysmans MCDNJM, and de Visscher JGAM
- Subjects
- Chronic Disease, Humans, Mouth Mucosa pathology, Quality of Life, Graft vs Host Disease drug therapy, Graft vs Host Disease etiology, Graft vs Host Disease pathology, Hematopoietic Stem Cell Transplantation adverse effects, Mouth Diseases diagnosis, Mouth Diseases etiology, Mouth Diseases therapy
- Abstract
Allogeneic stem cell transplantation can cause chronic graft versus host disease (cGVHD). A number of patients manifest cGVHD in and around the mouth. It can present itself as clinically as mucosal lesions and/or salivary gland dysfunction and/or sclerotic changes. Cheeks and tongue are most commonly affected, but the palate, gingiva and lips can also be impacted. Oral cGVHD is associated with mucosal sensitivity, pain, (severe) oral dryness, altered taste, restricted mouth opening and difficulty swallowing, all of which may contribute to a significant decrease of the patient's quality of life. Patients also run an increased risk of developing squamous cell carcinoma of the oral mucosa. The diagnosis of cGVHD is almost always based on the patient's medical history and clinical picture. Treatment of symptoms is based on the patient's problem(s). Dental professionals can provide patients with supportive preventive care aimed at reducing symptoms and preventing further deterioration of oral health.
- Published
- 2022
- Full Text
- View/download PDF
44. Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale.
- Author
-
Singer S, Hammerlid E, Tomaszewska IM, Amdal CD, Bjordal K, Herlofson BB, Santos M, Silva JC, Mehanna H, Fullerton A, Brannan C, Gonzalez LF, Inhestern J, Pinto M, Arraras JI, Yarom N, Bonomo P, Baumann I, Galalae R, Nicolatou-Galitis O, Kiyota N, Raber-Durlacher J, Salem D, Fabian A, Boehm A, Krejovic-Trivic S, Chie WC, Taylor K, Simon C, Licitra L, and Sherman AC
- Subjects
- Humans, Quality of Life psychology, Surveys and Questionnaires, Deglutition, Head and Neck Neoplasms therapy
- Abstract
Purpose: The aim of this study was to explore what methods should be used to determine the minimal important difference (MID) and minimal important change (MIC) in scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43., Methods: In an international multi-centre study, patients with head and neck cancer completed the EORTC QLQ-HN43 before the onset of treatment (t1), three months after baseline (t2), and six months after baseline (t3). The methods explored for determining the MID were: (1) group comparisons based on performance status; (2) 0.5 and 0.3 standard deviation and standard error of the mean. The methods examined for the MIC were patients' subjective change ratings and receiver-operating characteristics (ROC) curves, predictive modelling, standard deviation, and standard error of the mean. The EORTC QLQ-HN43 Swallowing scale was used to investigate these methods., Results: From 28 hospitals in 18 countries, 503 patients participated. Correlations with the performance status were |r|< 0.4 in 17 out of 19 scales; hence, performance status was regarded as an unsuitable anchor. The ROC approach yielded an implausible MIC and was also discarded. The remaining approaches worked well and delivered MID values ranging from 10 to 14; the MIC for deterioration ranged from 8 to 16 and the MIC for improvement from - 3 to - 14., Conclusions: For determining MIDs of the remaining scales of the EORTC QLQ-HN43, we will omit comparisons of groups based on the Karnofsky Performance Score. Other external anchors are needed instead. Distribution-based methods worked well and will be applied as a starting strategy for analyses. For the calculation of MICs, subjective change ratings, predictive modelling, and standard-deviation based approaches are suitable methods whereas ROC analyses seem to be inappropriate., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
45. [Medicaments and oral healthcare. Adverse effects of medications on the oral mucosa].
- Author
-
Rooijers W, Rademacher WHM, Raber-Durlacher JE, Aziz Y, Hielema AP, and Rozema FR
- Subjects
- Humans, Mouth Mucosa, Netherlands, Drug-Related Side Effects and Adverse Reactions, Oral Ulcer
- Abstract
Many medications prescribed in the Netherlands have adverse effects on the oral mucosa. Adverse events often described are stomatitis, white lesions, abnormal pigmentation and sensibility disorders. Stomatitis is frequently observed in patients using medications for the treatment of malignancies or auto-immune diseases. Important causative classes of medicines are alkylating agents, anthracyclines, monoclonal antibodies, protein kinase inhibitors, purine derivatives, pyrimidine antagonists, taxanes and vinca alkaloids. White oral lesions often concern candidiasis and are frequently seen in patients using certain immunosuppressants and antibiotics. Abnormal pigmentation is frequently seen in patients using hydroxycarbamide, an antineoplastic agent. Sensibility disorders of the oral mucosa are described in several classes of medications, including protein kinase inhibitors. It is very important oral healthcare professionals can recognise possible adverse effects of medications on the oral mucosa. When it is probable an anomaly of the oral mucosa is caused by medication, the oral healthcare professional should contact the prescribing physician to discuss the possibility of adjusting or discontinuing the medication.
- Published
- 2020
- Full Text
- View/download PDF
46. Photobiomodulation effects on head and neck squamous cell carcinoma (HNSCC) in an orthotopic animal model.
- Author
-
Barasch A, Li H, Rajasekhar VK, Raber-Durlacher J, Epstein JB, Carroll J, and Haimovitz-Friedman A
- Subjects
- Animals, Cell Line, Tumor, Dermatitis pathology, Disease Models, Animal, Humans, Mice, Mice, Nude, Mice, SCID, Neoplasm Transplantation, Stomatitis pathology, Transplantation, Heterologous, Low-Level Light Therapy adverse effects, Low-Level Light Therapy methods, Mucositis pathology, Radiotherapy adverse effects, Squamous Cell Carcinoma of Head and Neck radiotherapy
- Abstract
Background: Photobiomodulation (PBM) has shown efficacy in preventing and treating cancer therapy-induced mucositis and dermatitis. However, there is contradictory information regarding the effect of PBM on (pre)malignant cells, which has led to questions regarding the safety of this technique. We address this issue using an orthotopic mouse model (Cal-33) with human squamous cell carcinoma of the oral cavity., Methods: Mice with actively growing orthotopic Cal-33 head and neck carcinoma tumors were divided into 4 groups: control, PBM only, radiation therapy (RT) only, and PBM + RT. We performed three experiments: (1) PBM at 660 nm, 18.4 J/cm
2 , and 5 RT × 4 Gy doses delivered daily; (2) PBM at 660 nm, 18.4 J/cm2 , and 1 × 15 Gy RT; and (3) PBM at 660 nm + 850 nm, 45 mW/cm2 , 3.4 J/cm2 , and 1 × 15 Gy RT. Mice were weighed daily and tumor volumes were evaluated by IVIS. Survival time was also evaluated., Results: Animals treated with RT survived significantly longer and had significantly smaller tumor volume when compared with the control and PBM-only treatment groups. No significant differences were noted between the RT alone and PBM + RT groups in any of the experiments., Conclusion: Our results suggest that PBM at the utilized parameters does not provide protection to the tumor from the killing effects of RT.- Published
- 2020
- Full Text
- View/download PDF
47. [Oral graft-versus-host-disease: implications for dental professionals].
- Author
-
Raghoebar II, Raber-Durlacher JE, Laheij AMGA, and Rozema FR
- Subjects
- Chronic Disease, Humans, Mouth Mucosa, Dental Caries, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Xerostomia
- Abstract
Graft-versus-host disease (GVHD) is a serious complication after allogeneic hematopoietic stem cell transpl antation, which frequently affects the mouth. GVHD is the result of an immunological attack of donor-derived cells against the tissue of patients. Chronic oral GVHD can affect the mucosa and/or damage salivary glands and can cause sclerotic changes to the head and neck area. Patients can experience painful oral and gingival mucosa, dry mouth, taste changes and limited mouth opening. Due to painful mucosa and salivary glands, and limited mouth opening, performing oral hygiene and dental interventions can be difficult. Immunosuppression in combination with altered salivary production increases the risk of secondary infectious complications, such as dental caries and candida infections. Dental professionals can play an important role in the prevention of oral complications.
- Published
- 2020
- Full Text
- View/download PDF
48. International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV.
- Author
-
Singer S, Amdal CD, Hammerlid E, Tomaszewska IM, Castro Silva J, Mehanna H, Santos M, Inhestern J, Brannan C, Yarom N, Fullerton A, Pinto M, Arraras JI, Kiyota N, Bonomo P, Sherman AC, Baumann I, Galalae R, Fernandez Gonzalez L, Nicolatou-Galitis O, Abdel-Hafeez Z, Raber-Durlacher J, Schmalz C, Zotti P, Boehm A, Hofmeister D, Krejovic Trivic S, Loo S, Chie WC, Bjordal K, Brokstad Herlofson B, Grégoire V, and Licitra L
- Subjects
- Aged, Aged, 80 and over, Combined Modality Therapy, Europe, Female, Head and Neck Neoplasms complications, Head and Neck Neoplasms therapy, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Prospective Studies, Psychometrics, Reproducibility of Results, Sensitivity and Specificity, Head and Neck Neoplasms psychology, Quality of Life, Surveys and Questionnaires
- Abstract
Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43)., Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test-retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons., Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales., Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
49. Photobiomodulation therapy in the management of oral mucositis: search for the optimal clinical treatment parameters.
- Author
-
Elad S, Arany P, Bensadoun RJ, Epstein JB, Barasch A, and Raber-Durlacher J
- Subjects
- Humans, Low-Level Light Therapy methods, Stomatitis therapy
- Abstract
This commentary attempts to clarify the setting of photobiomodulation (BPM) therapy in the management of oral mucositis. The suggested dose range balances efficacy data with our current understanding about PBM safety. The literature about the molecular basis of photobiomodulation and its controversial relationship to malignant transformation is briefly presented.
- Published
- 2018
- Full Text
- View/download PDF
50. The effect of a single injection of irinotecan on the development of enamel in the Wistar rats.
- Author
-
Al-Ansari S, Jalali R, Bronckers T, Raber-Durlacher J, Logan R, de Lange J, and Rozema F
- Subjects
- Ameloblasts pathology, Animals, Calcification, Physiologic drug effects, Dental Enamel diagnostic imaging, Dental Enamel growth & development, Dental Enamel pathology, Female, Incisor diagnostic imaging, Incisor growth & development, Incisor pathology, Injections, Intraperitoneal, Mandible diagnostic imaging, Mandible drug effects, Mandible growth & development, Mandible pathology, Rats, Rats, Wistar, X-Ray Microtomography, Ameloblasts drug effects, Amelogenesis drug effects, Antineoplastic Agents adverse effects, Dental Enamel drug effects, Incisor drug effects, Irinotecan adverse effects
- Abstract
Cancer is the second most frequent cause of death in children. Because the prognosis for childhood malignancies has improved, attention has now focused on long-term consequences of cancer treatment. The immediate effects of chemotherapy on soft tissues have been well described; however, there is less information about long-term effects of chemotherapy on the development of dental tissues. To test the association between the effect of chemotherapy on enamel development, we examined two groups of rats: one that had received an intraperitoneal dose of 200 mg/kg of irinotecan, whereas the other (control) group had received vehicle only. Rats were killed at 6, 48 and 96 hr post-injection; the mandibles dissected out, fixed for histological evaluation and scanned for mineralization defects by Micro-CT. Our results showed structural changes in the ameloblast layer along with a significant reduction in mineralization and thickness of enamel at 96 hr after chemotherapy. These data demonstrate that irinotecan induces structural changes in forming enamel that become apparent after anticancer chemotherapy treatment., (© 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.